Contacts

Weilin Wang, doctor

CONTACT

+86 0571 87783820 wam@zju.edu.cn

Sponsors

Lead Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Collaborators

The First Affiliated Hospital of Zhengzhou University
The Affiliated Tumor Hospital of Xinjiang Medical University

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Histologically proven, unresectable advanced or metastatic cholangiocarcinoma patients.
•Expected survival period \> 12 weeks.
•The World Health Organization (WHO) / ECOG physical status (PS) was 0 or 1.
•There was at least one target lesion that matched the RECIST 1.1 criteria at baseline.
•Not previously received immunotherapy, including but not limited to CTLA 4, PD-L1 or/and PD-1 inhibitors.
•Adequate organ and bone marrow function, defined as follows: Hemoglobin (Hb)≥9.0g/dL; Neutrophils (ANC) ≥ 1.5\* 10\^9/L; Platelet (Pt) ≥ 50\*10\^9/L; ALT≤2.5×ULN（Normal upper limit); AST≤2.5×ULN.
•Voluntary participation and signing of informed consent.

Exclusion Criteria

•Active or previously documented autoimmune disease or inflammatory disease.
•Uncontrolled complications.
•History of other primary malignancies.
•Active infection.
•Women who are pregnant or breastfeeding.
•Patients with severe allergic history or specific constitution.
•Researchers consider it inappropriate to participate in the test.

Related studies

RECRUITINGPhase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more

RECRUITINGPhase 1

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

NCT06160752 · Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, and more

Active Not RecruitingPhase 2

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

NCT06178588 · Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, and more

Not Yet RecruitingPhase 3

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

NCT07328919 · Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma

TERMINATEDPhase 3

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

NCT04093362 · Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements

View all related studies →

Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Contacts

Sponsors

Related studies

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Trial snapshot

Condition

Locations shown

For caregivers